SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (694)12/2/1998 2:14:00 PM
From: Anthony Wong  Respond to of 2539
 
Goldman Sachs Summary (from mot Mouth of Yahoo MTC thread)
messages.yahoo.com@m2.yahoo.com

Mission accomplished. Bad news: Acute pain indications decision
deferred. Good news: (1)Panel unanimously recommended osteo &
rheumatoid arthritis approval (much bigger market). (2)Panel agreed
Celebrex's important benefits vs conventional NSAIDS need to be reflected
in labeling. (i)conventional NSAIDS label deemed not appropriate for
Celebrex. Rewording. (ii)Endoscopy data deemed relevant & permissible in
labeling (very favorable). (iii)Agreed that, unlike NSAIDS, Celebrex is okay
with aspirin, methotrexate, warfarin.(3)Approved 1-a-day OA data."